CSL Stock Analysis — CSL Limited
Sector: Healthcare
AI Verdict
CSL is cheap for a defensive healthcare name at 16.4x forward earnings, but without a pickup in growth beyond 9.7%, the moat alone may not drive multiple expansion.
Competitive Moat
CSL is a global leader in plasma-derived therapies and vaccines, with a moat built on its proprietary plasma collection network and regulatory barriers that make large-scale entry difficult. Its R&D pipeline and manufacturing scale reinforce its defensibility in rare disease treatment and immunology.
Summary
CSL stands out for its global plasma collection network, which underpins its dominance in specialized therapies.
Where It Stands
CSL trades at 16.4x next year's earnings, below the healthcare sector median of 22x, with analysts expecting 9.7% EPS growth and a trailing P/E of 18.0x.
Key Metrics
- Trailing P/E: 18.0x
- Forward P/E: 16.4x
- PEG Ratio: 1.85
- Earnings Growth: +0.1%
- Revenue Growth: +0.0%
- Dividend Yield: 0.01%
- 52-Week High: $432.91
- 52-Week Low: $293.43
Analyst Consensus
10 Buy · 7 Hold · 0 Sell (17 analysts)
Bull Case
With a forward P/E of 16.4x and 9.7% EPS growth expected, investors are paying a below-average multiple for steady earnings expansion anchored by CSL's plasma network.
Bear Case
If the forward P/E reverts to the sector median of 22x without a growth acceleration, upside is capped, and with just 1.9% trailing revenue growth, the market may not reward CSL with a premium.
Catalyst to Watch
Watch for clinical trial updates or regulatory approvals that could accelerate EPS growth above the current 9.7% forecast.